CA2384991A1 - Utilisation de la substance d'inhibition des canaux de muller pour le traitement des etats pathologiques caracterises par un exces d'androgenes - Google Patents

Utilisation de la substance d'inhibition des canaux de muller pour le traitement des etats pathologiques caracterises par un exces d'androgenes Download PDF

Info

Publication number
CA2384991A1
CA2384991A1 CA002384991A CA2384991A CA2384991A1 CA 2384991 A1 CA2384991 A1 CA 2384991A1 CA 002384991 A CA002384991 A CA 002384991A CA 2384991 A CA2384991 A CA 2384991A CA 2384991 A1 CA2384991 A1 CA 2384991A1
Authority
CA
Canada
Prior art keywords
mis
cells
kda
androgens
testosterone
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002384991A
Other languages
English (en)
Inventor
Patricia K. Donahoe
Jose Teixeira
Eric Fynn-Thompson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
General Hospital Corp
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2384991A1 publication Critical patent/CA2384991A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/28—Antiandrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Gynecology & Obstetrics (AREA)
  • Urology & Nephrology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Diabetes (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

La présente invention concerne une méthode de traitement d'un état pathologique ou d'une maladie caractérisé par un excès de un ou plusieurs androgènes. Cette méthode consiste à administrer à un patient une dose efficace d'une protéine d'inhibition des canaux de Müller (MIS) ou d'un acide nucléique codant pour ladite protéine MIS. La présente invention concerne également une méthode permettant de faire passer le niveau d'un ou de plusieurs androgènes en deçà du niveau normal, ladite méthode consistant à administrer à un patient une dose efficace d'une protéine MIS ou d'un acide nucléique codant pour ladite protéine MIS. Les méthodes selon la présente invention sont particulièrement indiquées pour le traitement du cancer de la prostate, des ovaires polykystiques, de l'hypertrophie bénigne de la prostate, et de la puberté précoce.
CA002384991A 1999-09-14 2000-09-14 Utilisation de la substance d'inhibition des canaux de muller pour le traitement des etats pathologiques caracterises par un exces d'androgenes Abandoned CA2384991A1 (fr)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US15367499P 1999-09-14 1999-09-14
US60/153,674 1999-09-14
US15394099P 1999-09-15 1999-09-15
US60/153,940 1999-09-15
PCT/US2000/025094 WO2001019387A1 (fr) 1999-09-14 2000-09-14 Utilisation de la substance d'inhibition des canaux de muller pour le traitement des etats pathologiques caracterises par un exces d'androgenes

Publications (1)

Publication Number Publication Date
CA2384991A1 true CA2384991A1 (fr) 2001-03-22

Family

ID=26850750

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002384991A Abandoned CA2384991A1 (fr) 1999-09-14 2000-09-14 Utilisation de la substance d'inhibition des canaux de muller pour le traitement des etats pathologiques caracterises par un exces d'androgenes

Country Status (5)

Country Link
EP (1) EP1218025A4 (fr)
JP (1) JP2003509377A (fr)
AU (1) AU7483000A (fr)
CA (1) CA2384991A1 (fr)
WO (1) WO2001019387A1 (fr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2853935T3 (es) * 2013-03-12 2021-09-20 Massachusetts Gen Hospital Proteínas modificadas de sustancia inhibidora muleriana (MIS) y usos de las mismas para el tratamiento de enfermedades
US10258668B2 (en) 2013-09-20 2019-04-16 The General Hospital Corporation Viral vectors for expressing a modified mullerian inhibiting substance (MIS) protein
AU2014362307A1 (en) 2013-12-11 2016-06-30 The General Hospital Corporation Use of mullerian inhibiting substance (MIS) proteins for contraception and ovarian reserve preservation
WO2018112168A1 (fr) 2016-12-14 2018-06-21 The General Hospital Corporation Protéines d'hormone anti-müllérienne (ham) pour l'oncoprotection ovarienne et utérine, et réserve ovarienne et conservation utérine

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5427780A (en) * 1985-10-30 1995-06-27 Biogen, Inc. Composition comprising Mullerian inhibiting substance-like polypeptides
US5047336A (en) * 1985-10-30 1991-09-10 Biogen, Inc. DNA sequences, recombinant DNA molecules and processes for producing mullerian inhibiting substance-like polypeptides
US5484768A (en) * 1990-05-16 1996-01-16 The University Of Melbourne Treatment of male infertility by administration of a muellerian inhibiting substance and surgery and/or hormonal treatment
AU3920693A (en) * 1992-03-18 1993-10-21 General Hospital Corporation, The Four novel receptors of the TGF-beta receptor family
JP2947938B2 (ja) * 1994-11-28 1999-09-13 旭化成工業株式会社 光記録媒体

Also Published As

Publication number Publication date
EP1218025A1 (fr) 2002-07-03
WO2001019387A1 (fr) 2001-03-22
EP1218025A4 (fr) 2005-06-01
JP2003509377A (ja) 2003-03-11
AU7483000A (en) 2001-04-17

Similar Documents

Publication Publication Date Title
EP0925360B1 (fr) Facteur angiogeniqueutilisation de facteur angiogenique vegf145 dans le traitement de maladies cardiovasculaires
US6479654B1 (en) Forms of the angiogenic factor vascular endothelial cell growth factor: VEGF
JP5813161B2 (ja) インビボにおいて送達される膵島転写因子遺伝子による膵島の再生及び糖尿病の回復
US6673352B1 (en) Use of Mullerian inhibiting substance for treating excess androgen states
AU7250298A (en) Truncated vegf-related proteins
US20090038022A1 (en) IGF-1 Novel peptides
JP2022180637A (ja) 疾患の治療のための改変されたミュラー管抑制物質（ｍｉｓ）タンパク質およびその使用
US20190351026A1 (en) Uses of modified mullerian inhibiting substance (mis) proteins for the treatment of neurodegenerative diseases
CA2384991A1 (fr) Utilisation de la substance d'inhibition des canaux de muller pour le traitement des etats pathologiques caracterises par un exces d'androgenes
JP2004517884A (ja) グルココルチコイド濃度の調節
US20030165467A1 (en) Angiogenic factor and use thereof in treating cardiovascular disease
US20040198705A1 (en) Modulation of steroid hormone uptake
US20040151693A1 (en) Use of mullerian inhibiting substance and interferon for treating tumors
EP1426444A2 (fr) Utilisation du facteur d'angiogénèse VEGF145 dans le traitement de maladies cardiovasculaires
US20060084622A1 (en) Angiogenic factor and use thereof in treating cardiovascular disease
AU8936101A (en) Angiogenic factor and use thereof in treating cardiovascular disease
AU2004200697A1 (en) Variants of the Angiogenic Factor Vascular Endothelial Cell Growth Factor: VEGF

Legal Events

Date Code Title Description
EEER Examination request
FZDE Dead